New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
12:02 EDTMRK, MYLMerck win over Mylan related to Zetia, Vytorin patents upheld on appeal
The U.S. Court of Appeals for the Federal Circuit affirmed a lower court ruling in Merck's (MRK) favor in two jointly related patent infringement suits against Mylan Pharmaceuticals (MYL). The lower court previously found that Merck's patent which covers ezetimibe, an active ingredient in both Zetia and Vytorin, was valid and enforceable. The lower court also issued an injunction blocking the approval of Mylan's generic versions until the expiration of Merck's patent. Reference Link
News For MRK;MYL From The Last 14 Days
Check below for free stories on MRK;MYL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
April 6, 2014
13:37 EDTMRKMerck presents findings on clinical outcomes following treatment with MK-3475
Subscribe for More Information
April 4, 2014
12:09 EDTMYLOn The Fly: Midday Wrap
Subscribe for More Information
10:45 EDTMYLMylan rises despite Meda rejecting takeover offer
Mylan (MYL) shares are higher this morning following a Financial Times report of its desire to buy Swedish rival Meda. Subsequent to the story being published, Meda confirmed it had been in talks with Mylan but rejected the company's takeover offer. WHAT'S NEW: The Financial Times reported that Mylan was considering buying Meda, a Swedish drugmaker, in a deal that would create a $23B+ pharmaceuticals business. Mylan reportedly hired advisers to put a deal together for Meda, and though the value of a deal was not noted, sources said Mylan was likely to pay a "significant" premium to Meda's market value, which was $4.5B at the end of trading on Thursday. Mylan's market value currently stands at $18.5B. A combination of the drugmakers would create a company with annual revenues of around $9B, the FT said, noting that would be half the size of generic drug rival Teva (TEVA). WHAT'S NOTABLE: Meda's board of directors confirmed that it was contacted by Mylan regarding a proposal to merge the companies, but the board decided to reject the proposal. Meda said all discussions between the company and Mylan have been terminated "without further actions." ANALYST REACTION: Citigroup upgraded Mylan to Buy from Neutral and raised its price target on the stock to $61 from $52 this morning. The firm cited potential operational and tax benefits from an acquisition of Meda, stating that in addition to expanding Mylan's geographic presence, the deal would increase its presence in specialty, OTC and branded generics. OTHER NEWS: Mylan sued Celgene (CELG) to block that company's efforts to keep generic versions of Revlimid and Thalomid off the market, Reuters reported. PRICE ACTION: Mylan shares are up $2.98, or 5.98%, to $52.84 in mid-morning trading.
10:02 EDTMYLOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:13 EDTMYLOn The Fly: Pre-market Movers
HIGHER: Mylan (MYL), up 6.8% after report of desire to buy Swedish rival Meda, which confirmed it had been in talks with Mylan but rejected the company's takeover offer. Shares of Mylan were also upgraded to Buy this morning at Citigroup... Mercury Systems (MRCY), up 8.8% after Reuters said Boeing (BA) is considering a takeover bid of the supplier..Micron (MU), up 3% after reporting earnings and revenue that topped expectations... Align (ALGN), up 6% after winning patent case against ClearCorrect... GameStop (GME), up 2.8% following upgrade at BofA Merrill Lynch... Potbelly (PBPB), up 4.6% after upgrade at William Blair.... SYNNEX (SNX), up 18.5% after earnings report. LOWER: CarMax (KMX), down 3.3% after reporting earnings and revenue that fell below expectations... Halozyme (HALO), down 33% after announcing temporary halt of Phase 2 trial enrollment for PEGPH20... Ocean Power (OPTT), down 15% after 3.8M share Spot Secondary priced at $3.10.
09:07 EDTMYLMylan off highs, shares still up 5% after Meda ends takeover talks
Subscribe for More Information
09:06 EDTMYLMeda ends talks with Mylan, rejects takeover proposal
Subscribe for More Information
09:02 EDTMYLMeda says 'decided to reject' proposal from Mylan
09:00 EDTMYLMylan rises 10.7%
Subscribe for More Information
08:46 EDTMYLMylan upgraded to Buy from Neutral at Citigroup
Citigroup upgraded Mylan to Buy citing potential operational and tax benefits from an acquisition of Swedish-based Meda. Mylan is in preliminary talks to acquire Meda, according to the Financial Times. Citi raised its price target for shares to $61 from $52.
08:39 EDTMYLMylan upgraded to Buy from Neutral at Citigroup
Subscribe for More Information
08:07 EDTMRKMerck, Ferring announce collaboration with WHO
Merck and Ferring Pharmaceuticals announced their collaboration with the World Health Organization to advance a new, proprietary formulation of carbetocin, used to prevent excessive bleeding in women after childbirth, that is designed to be stable at room temperature, even in hot and tropical climates. Currently, oxytocin, the standard medicine administered for the prevention of excessive bleeding, is temperature-sensitive and requires sustained cold distribution and storage in hot climates. The WHO will conduct a multi-country clinical study to evaluate the effectiveness of room-temperature-stable carbetocin, as compared to oxytocin. The development of a medicine that can be stored at room temperature has the potential to significantly improve management of bleeding following childbirth in the many areas of the world where cold storage is difficult to achieve and maintain, and thereby help reduce maternal deaths in those areas. Starting this year, the study will take place in 12 countries around the world and enroll approximately 29,000 women. If the results of the study are positive, the organizations will work together with the aim of making the medicine available in developing countries that have a high burden of maternal mortality at an affordable and sustainable public-sector price.
07:45 EDTMYLMylan volatility expected to move on looking at buying Swedish drug maker Meda
Subscribe for More Information
06:49 EDTMYLMylan sues Celgene for blocking Thalomid, Revlimid generics, Reuters says
Subscribe for More Information
06:44 EDTMYLMeda chairman says firm had preliminary discussions with Mylan, Reuters says
Subscribe for More Information
06:08 EDTMYLMylan eyes takeover of Swedish rival Meda, FT reports
Subscribe for More Information
April 3, 2014
14:30 EDTMYLMylan says USPTO rejects Teva '808 patent reissue application on Copaxone
Subscribe for More Information
14:28 EDTMYLMylan says USPTO rejects Teva '808 patent reissue application on Copaxone
Subscribe for More Information
06:04 EDTMYLMylan implied volatility of 44 at upper end of index mean range
April 2, 2014
11:14 EDTMYLOptions with increasing implied volatility: ATHN ISRG MYL
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use